Featured Research

from universities, journals, and other organizations

PXR: A stepping stone from environmental chemical to cancer?

Date:
July 11, 2011
Source:
Journal of Clinical Investigation
Summary:
Several chemicals that can accumulate to high levels in our body (for example, BPA and some pesticides) have been recently linked to an increased risk of cancer and/or impaired responsiveness to anticancer drugs. Researchers have now identified a potential mechanistic link between environmental exposure to these foreign chemicals (xenogens) and cancer drug therapy response and survival.

Several chemicals that can accumulate to high levels in our body (for example, BPA and some pesticides) have been recently linked to an increased risk of cancer and/or impaired responsiveness to anticancer drugs. A team of researchers, led by Sridhar Mani, at Albert Einstein College of Medicine, New York, has now identified a potential mechanistic link between environmental exposure to these foreign chemicals (xenogens) and cancer drug therapy response and survival.

PXR is one protein by which cells (including tumor cells) can sense xenogens. In their study, Mani and colleagues determined that activation of PXR was sufficient to enhance the cancerous characteristics of human colon tumor cell lines and primary human colon cancer tissue xenografted into immune system-deficient mice. Further analysis indicated FXR activation leads to colon cancer growth through the induction of the growth factor FGF19.

The authors therefore suggest that it will be important to investigate further the extent to which the environment might play a role in tumor recurrence through PXR activation.

The research is published in the Journal of Clinical Investigation.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hongwei Wang, Madhukumar Venkatesh, Hao Li, Regina Goetz, Subhajit Mukherjee, Arunima Biswas, Liang Zhu, Andreas Kaubisch, Lei Wang, James Pullman, Kathleen Whitney, Makoto Kuro-o, Andres I. Roig, Jerry W. Shay, Moosa Mohammadi, Sridhar Mani. Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. Journal of Clinical Investigation, 2011; DOI: 10.1172/JCI41514

Cite This Page:

Journal of Clinical Investigation. "PXR: A stepping stone from environmental chemical to cancer?." ScienceDaily. ScienceDaily, 11 July 2011. <www.sciencedaily.com/releases/2011/07/110711131320.htm>.
Journal of Clinical Investigation. (2011, July 11). PXR: A stepping stone from environmental chemical to cancer?. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/07/110711131320.htm
Journal of Clinical Investigation. "PXR: A stepping stone from environmental chemical to cancer?." ScienceDaily. www.sciencedaily.com/releases/2011/07/110711131320.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins